search
Back to results

Efficacy of the "Milk Ladder" Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins

Primary Purpose

IgE-mediated Milk Allergy

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Milk
Sponsored by
Hospital San Carlos, Madrid
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for IgE-mediated Milk Allergy

Eligibility Criteria

1 Month - 12 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Babies of both sexes.
  • Age < 12 months.
  • Clinical history of immediate reaction (<2 hours) after the intake of baby's formula and/or foods containing cow's milk.
  • Sensitization to cow's milk proteins demonstrated by:

    • sIgE to cow's milk, alpha-Lactoabumin, beta-Lactoglobulin and/or Casein >0.1KU/l (ImmunoCAP®, ThemoFisher) and/or
    • Skin prick test to cow's milk, alpha-Lactoabumin, beta-Lactoglobulin and/or Casein ≥3mm
  • If the reaction to milk occurred over 3 months before the recruitment, it will be mandatory to confirm reactivity to milk with an oral food test.
  • Parents / legal representatives of the participant voluntary accept to participate.

Exclusion Criteria:

  • Delayed reactions (> 2 h) after milk intake.
  • Contact urticaria to milk if ingestion is well tolerated.
  • Previous participation in oral tolerance induction/desensitization protocols.
  • Treatment with any medication that might interfere the evaluation of the primary outcome or any study procedure.
  • Any disease or condition which presents a contraindication to perform an oral challenge, either open or double-blind or any other study procedure.
  • Social circumstances that might interfere with protocol adherence.
  • Egg and/or wheat allergy (this exclusion criterion shall be verified before the beginning of the intervention).

Sites / Locations

  • Hospital Clinico San CarlosRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Dietary intervention

Historical cohort

Arm Description

Meals containing Milk and Milk

Standard care

Outcomes

Primary Outcome Measures

Number of participants that develop tolerance to milk after the 'Milk Ladder' intervention
Tolerance assessment: participants who successfully pass a double-blind placebo-controlled oral food challenge without experiencing any limiting symptom
Number of participants experiencing any adverse reaction
Number of participants experiencing any adverse reaction to milk-containing foods along the intervention assessed by Medical Dictionary for Regulatory Activities (MedDRA), version in place at the end of the study.
Change in antigen-specific IgE and IgG4 epitopes repertoire
Serum specific inmunnoglobulin levels using a milk peptide microarray immunoassay

Secondary Outcome Measures

Quality of life
Change in quality of life total score during the intervention, assessed by the disease-specific questionnaire 'Food Allergy Quality of Life Questionnaire - Parent Form'
Potential T-cell epitopes
Identification of potential T-cell epitopes in serum assessed by a T lymphocyte proliferation assay and cytokine secretion
Ability of the milk allergenic peptides to activate basophils
In vitro determination of basophil activation upon antigen stimulation

Full Information

First Posted
February 2, 2018
Last Updated
June 25, 2020
Sponsor
Hospital San Carlos, Madrid
search

1. Study Identification

Unique Protocol Identification Number
NCT03466931
Brief Title
Efficacy of the "Milk Ladder" Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins
Official Title
Efficacy of the "Milk Ladder" Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2018 (Actual)
Primary Completion Date
June 1, 2021 (Anticipated)
Study Completion Date
August 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital San Carlos, Madrid

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Food allergies have become a relevant health problem in westernized societies, particularly, with children. Cow's milk (CM), along with hen's eggs, are the most common foods eliciting allergic reactions in children under 4 years of age. The main objective of this intervention study is to evaluate the safety and efficacy of the intervention known as "The Milk Ladder" in the development of tolerance by children with CM allergies. This will be compared to an historical cohort (CoALE), which investigated the natural history of this allergy. Additionally, the ability of informative epitopes will be evaluated for their potential to predict tolerance and their correlation against clinical variables. The "Milk Ladder" will be evaluated within a prospective cohort of CM allergic children. This intervention is enacted through the introduction of meals cooked with progressively increasing amounts of cow's milk into the participant's diet. The primary outcome will be the development of tolerance which will be evaluated through a double-blind placebo-controlled food challenge. IgE and IgG4 epitopes will be described using a peptide microarray immunoassay. Quality of life will be determined by administering the FAQLQ-PF disease-specific questionnaire. Finally, within a subgroup of study participants, the ability of different peptides to activate basophils will be analyzed, and CM T cell epitopes will be studied by means of T-cell proliferation and cytokine production assays.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IgE-mediated Milk Allergy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
114 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dietary intervention
Arm Type
Experimental
Arm Description
Meals containing Milk and Milk
Arm Title
Historical cohort
Arm Type
No Intervention
Arm Description
Standard care
Intervention Type
Other
Intervention Name(s)
Milk
Intervention Description
Meals containing Milk and Milk
Primary Outcome Measure Information:
Title
Number of participants that develop tolerance to milk after the 'Milk Ladder' intervention
Description
Tolerance assessment: participants who successfully pass a double-blind placebo-controlled oral food challenge without experiencing any limiting symptom
Time Frame
12 months
Title
Number of participants experiencing any adverse reaction
Description
Number of participants experiencing any adverse reaction to milk-containing foods along the intervention assessed by Medical Dictionary for Regulatory Activities (MedDRA), version in place at the end of the study.
Time Frame
12 months
Title
Change in antigen-specific IgE and IgG4 epitopes repertoire
Description
Serum specific inmunnoglobulin levels using a milk peptide microarray immunoassay
Time Frame
6 and 18 months
Secondary Outcome Measure Information:
Title
Quality of life
Description
Change in quality of life total score during the intervention, assessed by the disease-specific questionnaire 'Food Allergy Quality of Life Questionnaire - Parent Form'
Time Frame
6 and 18 months
Title
Potential T-cell epitopes
Description
Identification of potential T-cell epitopes in serum assessed by a T lymphocyte proliferation assay and cytokine secretion
Time Frame
12 months
Title
Ability of the milk allergenic peptides to activate basophils
Description
In vitro determination of basophil activation upon antigen stimulation
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
12 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Babies of both sexes. Age < 12 months. Clinical history of immediate reaction (<2 hours) after the intake of baby's formula and/or foods containing cow's milk. Sensitization to cow's milk proteins demonstrated by: sIgE to cow's milk, alpha-Lactoabumin, beta-Lactoglobulin and/or Casein >0.1KU/l (ImmunoCAP®, ThemoFisher) and/or Skin prick test to cow's milk, alpha-Lactoabumin, beta-Lactoglobulin and/or Casein ≥3mm If the reaction to milk occurred over 3 months before the recruitment, it will be mandatory to confirm reactivity to milk with an oral food test. Parents / legal representatives of the participant voluntary accept to participate. Exclusion Criteria: Delayed reactions (> 2 h) after milk intake. Contact urticaria to milk if ingestion is well tolerated. Previous participation in oral tolerance induction/desensitization protocols. Treatment with any medication that might interfere the evaluation of the primary outcome or any study procedure. Any disease or condition which presents a contraindication to perform an oral challenge, either open or double-blind or any other study procedure. Social circumstances that might interfere with protocol adherence. Egg and/or wheat allergy (this exclusion criterion shall be verified before the beginning of the intervention).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Inmaculada Cerecedo, MD, PhD
Phone
+ 34 913303000
Ext
7454
Email
Inmaculada.cerecedo@salud.madrid.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Inmaculada Cerecedo, e: MD, PhD
Organizational Affiliation
Hospital Clinico San Carlos
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Inmuculada Cerecedo, MD, PhD
Phone
+ 34 91 330 30 00
Ext
7454
Email
inmaculada.cerecedo@salud.madrid.org

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Efficacy of the "Milk Ladder" Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins

We'll reach out to this number within 24 hrs